"The DNA Replication Licensing Factor Tah11 (Cdt1) Functions to Protect Cells From Camptothecin and Replication Fork Arrest"

Hervé Jacquiau, Ph.D. is one of the authors of this article which discusses how Camptothecin (CPT) targets DNA topoisomerase I by reversibly stabilizing a covalent enzyme-DNA intermediate. The cytotoxic activity of the drug, however, is S-phase dependent and results from the collision of advancing replication forks with the ternary CPT-Top1-DNA complexes. The response of S-phase and DNA damage checkpoints to CPT-induced lesions is consistent with this cytotoxic mechanism. However, the molecular interactions required to elicit these cytotoxic lesions during S-phase and the nature of the lesion(s) induced remain largely unknown.

Hervé Jacquiau, Ph.D., assists in all aspects of patent practice, including patent prosecution and litigation. His background covers a variety of technologies, particularly biotechnology, bioengineering, biochemistry, molecular biology and microbiology. Hervé received his Ph.D. degree from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants.

To read the article abstract, please click the link below: